Topical silymarin administration for prevention of acute radiodermatitis in breast cancer patients: A randomized, double‐blind, placebo‐controlled clinical trial

Radiation‐induced dermatitis is one of the most common side effects of radiotherapy. Silymarin, a flavonoid extracted from the Silybum marianum, exhibits antioxidant and anti‐inflammatory activities. The purpose of this study was to investigate the efficacy of silymarin gel in prevention of radioder...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2019-02, Vol.33 (2), p.379-386
Main Authors: Karbasforooshan, Hedyieh, Hosseini, Sare, Elyasi, Sepideh, Fani Pakdel, Azar, Karimi, Gholamreza
Format: Article
Language:English
Subjects:
Administration, Topical
Adult
Antioxidants
Antioxidants - administration & dosage
Antioxidants - therapeutic use
Breast cancer
Breast Neoplasms - therapy
Cancer
Clinical trials
Delay
Dermatitis
Double-Blind Method
Double-blind studies
Evaluation
Female
Humans
Inflammation
Mastectomy
Mastectomy - methods
Middle Aged
Oncology
Patients
Prevention
Radiation
Radiation therapy
radiodermatitis
Radiodermatitis - prevention & control
radiotherapy
Randomization
Side effects
Silybum marianum
Silybum marianum - chemistry
Silymarin
Silymarin - administration & dosage
Silymarin - pharmacology
Skin
Terminology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Radiation‐induced dermatitis is one of the most common side effects of radiotherapy. Silymarin, a flavonoid extracted from the Silybum marianum, exhibits antioxidant and anti‐inflammatory activities. The purpose of this study was to investigate the efficacy of silymarin gel in prevention of radiodermatitis in patients with breast cancer. During this randomized, double‐blinded, placebo‐controlled clinical trial, the preventive effect of silymarin 1% gel was assessed in comparison with placebo, on radiodermatitis occurrence. Forty patients randomly received silymarin gel or placebo formulation on chest wall skin following modified radical mastectomy, once daily starting at the first day of radiotherapy for 5 weeks. Radiodermatitis severity was assessed weekly based on Radiation Therapy Oncology Group (RTOG) and National Cancer Institute Common Terminology for Adverse Events (NCI‐CTCAE) criteria radiodermatits grading scale for 5 weeks. The median NCI‐CTCAE and RTOG scores were significantly lower in silymarin group at the end of the third to fifth weeks (p value 
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.6231